Ratings Paxman AB

Equities

PAX

SE0009806284

Delayed Nasdaq Stockholm Other stock markets 07:57:50 2024-04-26 am EDT			5-day change	1st Jan Change
36.5 ^SEK	+3.11%		+4.58%	-0.82%

Jan. 15	Paxman AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Paxman AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The company is in a robust financial situation considering its net cash and margin position.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 35.4 times its estimated earnings per share for the ongoing year.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
PAXMAN AB	-0.82%	61.72M	D
ABBOTT LABORATORIES	-2.92%	185B	C+
MEDTRONIC PLC	-3.80%	105B	C
BECTON, DICKINSON AND COMPANY	-5.48%	66.59B	A
DEXCOM, INC.	+11.22%	54.66B	B-
CENCORA, INC.	+16.74%	47.78B	B-
HOYA CORPORATION	+4.06%	41.26B	B+
WEST PHARMACEUTICAL SERVICES, INC.	+4.56%	26.95B	A-
METTLER-TOLEDO INTERNATIONAL, INC.	+1.64%	26.37B	B
TERUMO CORPORATION	+12.96%	24.8B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders